Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Myelodysplastic Syndrome
Related studies linked through entity extraction aliases.
Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA
- Status
- TERMINATED
- Phase
- PHASE3
Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies
- Status
- COMPLETED
- Phase
- PHASE2
Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies
- Status
- TERMINATED
- Phase
- PHASE1
IPA Targeted Adoptive Immunotherapy vs Adult Haplo-identical Cell Infusion During Induction of High Risk Leukemia
- Status
- TERMINATED
- Phase
- PHASE2
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor
- Status
- COMPLETED
- Phase
- PHASE2
Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation
- Status
- COMPLETED
- Phase
- PHASE1
Allo-HSCT With Alternative Donor in Treatment of Hematologic Malignancy
- Status
- COMPLETED
- Phase
- NA
Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant
- Status
- COMPLETED
- Phase
- PHASE1
Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation
- Status
- COMPLETED
- Phase
- PHASE2
Study of Clinical Efficacy and Safety of Tosedostat in MDS
- Status
- COMPLETED
- Phase
- PHASE2
Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML)
- Status
- COMPLETED
- Phase
- PHASE2
Study of DSP-7888 in Patients With Myelodysplastic Syndrome
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2